Make the exclusion zones for pro-life activists larger
- 27 Signatures
(Estimated Final Signatures: 35 - 2 added in the past 24hrs)
Make it law that the exclusion zones are widened beyond the current 150m to make it more difficult for pro-life activists to protest anywhere near abortion clinics.
Found: Make the exclusion zones for pro-life activists larger
May. 26 2023
Source Page: Pro-innovation Regulation of Technologies Review: Life Sciences and the government responseFound: Pro-innovation Regulation of Technologies Review: Life Sciences and the government response
May. 26 2023
Source Page: Pro-innovation Regulation of Technologies Review: Life Sciences and the government responseFound: Pro-innovation Regulation of Technologies Review: Life Sciences and the government response
May. 26 2023
Source Page: Pro-innovation Regulation of Technologies Review: Life Sciences and the government responseFound: Pro-innovation Regulation of Technologies Review: Life Sciences and the government response
Mentions:
1: None The pro-life vigil gave me the hope I was searching for.Had I not received the support from volunteers - Speech Link
2: None However, you will very often hear pro-abortion campaigners saying that pro-life campaigners misuse evidence - Speech Link
3: None If a church is sited within an access zone, it could have a pro-life prayer meeting. - Speech Link
4: None might always have had a little pro-life sign in their window. - Speech Link
5: None People have talked a lot about having a pro-life poster, for instance. - Speech Link
Found: Review of research and recommendations for practice’, March 2010, p vii. 5 All Party Parliamentary Pro
Found: Review of research and recommendations for practice’, March 2010, p vii. 5 All Party Parliamentary Pro
Jun. 14 2023
Source Page: I. Biomanufacturing Fund Scheme guidance. 12p. II. Commercial clinical trials in the UK: the Lord O’Shaughnessy review. Final report. Incl. annexes. 75p. III. Response to Professor Dame Angela McLean’s Pro-Innovation Regulation of Technologies Review. Life Sciences. 18p. IV. Pro-innovation Regulation of Technologies Review. Life Sciences [presented by Professor Dame Angela McLean]. 23p. V. Government response to the Lord O’Shaughnessy review into commercial clinical trials in the UK. 7p.Found: Response to Professor Dame Angela McLean’s Pro-Innovation Regulation of Technologies Review.
Jun. 14 2023
Source Page: I. Biomanufacturing Fund Scheme guidance. 12p. II. Commercial clinical trials in the UK: the Lord O’Shaughnessy review. Final report. Incl. annexes. 75p. III. Response to Professor Dame Angela McLean’s Pro-Innovation Regulation of Technologies Review. Life Sciences. 18p. IV. Pro-innovation Regulation of Technologies Review. Life Sciences [presented by Professor Dame Angela McLean]. 23p. V. Government response to the Lord O’Shaughnessy review into commercial clinical trials in the UK. 7p.Found: Response to Professor Dame Angela McLean’s Pro-Innovation Regulation of Technologies Review.
Asked by: Rachael Maskell (Labour (Co-op) - York Central)
Question to the Department for Science, Innovation & Technology:
To ask the Secretary of State for Science, Innovation and Technology, whether she is taking steps with the Secretary of State for Health and Social Care to tackle regulatory systems that slow down research.
Answered by Andrew Griffith - Minister of State (Department for Science, Innovation and Technology)
Government is committed to delivering a regulatory system that is pro-innovation, easy to navigate and facilitates commercialisation of science and technology applications, as set out in the Science and Technology Framework.
Regulatory systems for life sciences are led by DHSC, and its arms-length-body the Medicines and Healthcare products Regulatory Agency recently launched a new, streamlined process for clinical trial applicants. The Department works with DHSC wherever appropriate on regulatory matters; for example, delivering the Government Chief Scientific Adviser's life sciences review and supporting on the wider implementation of the O'Shaughnessy Review into commercial clinical trials.